Food allergy is a complex and potentially life-threatening condition that requires a multidisciplinary approach to diagnosis, prevention, and treatment. Yet confusion persists among clinicians regarding the accurate identification and management of food allergies, particularly in differentiating between IgE-mediated reactions, non-IgE-mediated allergies, and food intolerances. Simultaneously, rapid advancements in therapy—including immunotherapies and biologics—are creating new opportunities for proactive and personalized care.

Host: Gerald Lee, MD, FACAAI
Experts: Edwin H. Kim, MD, FACAAI; Julie Wang, MD, FACAAI

This episode is not eligible for CME.


To download the mp3 file, right click on the player and select Save audio as.

Learning Objectives:

  1. Distinguish between IgE-mediated and non-IgE-mediated food allergies and food intolerances.
  2. Apply current evidence-based guidelines for early food allergy prevention and diagnosis.
  3. Describe the clinical application of oral, sublingual, and epicutaneous immunotherapy for food allergy.
  4. Evaluate the role of biologic therapies, such as omalizumab, in the management of complex or refractory food allergy cases.

References:

  1. Bartha, I., Almulhem, N., & Santos, A. F. (2024). Feast for thought: A comprehensive review of food allergy 2021-2023. The Journal of allergy and clinical immunology, 153(3), 576–594.
  2. Anagnostou, A., Greenhawt, M., Shaker, M., Vickery, B. P., & Wang, J. (2025). Food allergy yardstick: Where does omalizumab fit?. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology, 134(1), 110–121.

Speaker Disclosures:

Gerald Lee, MD, FACAAI
Nothing relevant to disclose.

Julie Wang, MD, FACAAI
Nothing relevant to disclose.

Edwin H. Kim, MD, FACAAI
Nothing relevant to disclose.

This podcast series is supported by Genentech.